Early Performance of a Multifilament Resorbable Synthetic Mesh in Aesthetic Breast Surgery: A 206 Patient Experience

Increasing evidence supports the role of soft-tissue reinforcement in enhancing outcomes and longevity in breast surgery. Maintenance of lower pole shape, soft-tissue support and implant position often requires use of mesh in aesthetic procedures. The authors describe their experience utilizing a fully resorbable multifilament scaffold (TIGR® Matrix, Novus Scientific, Uppsala, Sweden) as an alternative to biologic and synthetic meshes.

To assess early safety and performance outcomes when TIGR Matrix is utilized in primary and revision cosmetic breast surgery.

We began routinely utilizing TIGR matrix in aesthetic breast surgeries in 2023 and retrospectively reviewed all patients who underwent primary or revision elective cases with the mesh. Indication for use and examination of product performance was performed via a retrospective review.

TIGR matrix was used in 206 patients (407 breasts), mean age 42.6 years, with mean follow-up of 9.2 months. Mean BMI was 24.2 with 30 patients (14.6%) having a history of massive or major weight loss. One hundred fourteen cases (55.3%) were primary procedures, 92 (44.7%) were revisions. Mesh was placed in the subfascial position in 97 (47.1%) cases and submuscular in 109 (52.9%). Ten patients (4.9%) required postoperative intervention; 5 seromas in 4 patients (1.9%) required mesh removal and implant exchange and 6 patients required revision surgeries due to animation deformity (5) and implant displacement (1).

Use of TIGR matrix demonstrated early safety and effectiveness, achieving consistent clinical outcomes in both primary and revision aesthetic breast surgeries.